I didn't include the milestone payments but I did take into account the US vs AU financial years. The Axiron figures are taken from slide 6 of the investor presentation from April 28.
Can we guess the royalty stream?
The ACR half-year accounts from 20 Feb suggest revenue to ACR from Axiron is AUD14.3 Million (42.5M total includes 28.2M milestone)
This ACR half-year period corresponds with the Eli Lilly sales of calendar Q3 and Q4 2013 which is USD40.6M and USD53.9M respectively, a total of USD94.5M. Assuming a constant currency that roughly equates to 15%.
Last quarter's USD sales were USD 39.5M. Using 15% as a rough guide that is AUD 5.925M to ACR. Add that to the half-year revenue and you get approx. 20.3M for the first 9 months.
Another flat quarter would get them to about AUD26M for the year, which is shy of your 30 million for an 8c dividend.
Add to My Watchlist
What is My Watchlist?
